Patents Examined by Ekaterina Poliakova-Georgantas
  • Patent number: 10597660
    Abstract: The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: March 24, 2020
    Assignee: VOYAGER THERAPEUTICS, INC.
    Inventors: Dinah Wen-Yee Sah, Jinzhao Hou, Mathieu E. Nonnenmacher, Pengcheng Zhou, Markus Hossbach, Jochen Deckert
  • Patent number: 10590425
    Abstract: Methods and compositions are provided for oligonucleotides that bind targets of interest. The targets include cells and microvesicles, such as those derived from various diseases. The oligonucleotides can be used for diagnostic and therapeutic purposes. The target of the oligonucleotides can be a therapeutic target such as Complement Component 1, Q Subcomponent (C1q) or a subunit thereof.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: March 17, 2020
    Assignee: Caris Science, Inc.
    Inventors: Heather O'Neill, Mark Miglarese, David Spetzler
  • Patent number: 10584340
    Abstract: DNA aptamers that bind to tau protein at its phosphorylatable sites are identified. These disclosed DNA aptamers not only recognize tau at specific phosphorylatable sites, but also demonstrate inhibitory effects on phosphorylation and oligomer formation of tau protein. Molecular probes based on these disclosed DNA aptamers can be used as capture or detection agents to detect the levels of tau and phosphor-tau in cerebrospinal fluid as well as for cell-based or in vivo brain imaging in live animals or human. Compositions comprising these disclosed DNA aptamers can be used to arrest or treat the progression of tauopathy associated neurodegenerative disorders.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: March 10, 2020
    Assignees: University of Florida Research Foundation, Inc., Department of Veteran's Affairs
    Inventors: Ka W. Wang, Weihong Tan, Xiaowei Li, Hamad Yadikar, I-Ting Teng
  • Patent number: 10583149
    Abstract: The invention relates to the diagnostic and therapeutic uses of a miRNA molecule, an equivalent or a source thereof in a disease and condition associated with melanoma or a disease or a condition associated with activated BRAF pathway.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: March 10, 2020
    Assignees: INTERA TECHNOLOGIES B.V., KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN
    Inventors: Eugene Berezikov, Jos Bernard Poell, Willemijn Maria Gommans, Rick Jan van Haastert, Andreas Alphons F. L. van Puijenbroek, Roeland Quirinus Jozef Schaapveld, Gregoire Pierre Andre Prevost
  • Patent number: 10584341
    Abstract: Aptamers that bind to and antagonize PDL1 and uses thereof in enhancing immune activity (e.g., promoting T cell proliferation), treating cancer, and/or infectious diseases such as infections caused by enterovirus, HBV, or HCV infection.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: March 10, 2020
    Assignees: Academia Sinica, National Taiwan University
    Inventors: Pan-Chyr Yang, Wei-Yun Lai, Bo-Tsang Huang
  • Patent number: 10577665
    Abstract: Provided herein are aptamers, aptamer probes and biosensor systems that detect C. difficile glutamate dehydrogenase (GDH). Also provided are methods of detecting C. difficile GDH using the aptamers, probes and biosensors and methods of determining whether a subject has a C. difficile infection.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: March 3, 2020
    Assignee: McMaster University
    Inventors: Yingfu Li, John D. Brennan, Meng Liu
  • Patent number: 10577610
    Abstract: The present disclosure relates to an EpCAM aptamer or an EpCAM aptamer conjugate having bi-functional activity and to uses thereof. In particular, the present disclosure also relates to an aptamer conjugate which binds to the transferrin receptor (TfR) and EpCAM which is useful for treatment of brain tumours and/or brain metastasis.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: March 3, 2020
    Assignee: Deakin University
    Inventor: Sarah Shigdar
  • Patent number: 10563202
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Sirtuin (SIRT), in particular, by targeting natural antisense polynucleotides of a Sirtuin (SIRT). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Sirtuins (SIRT)s.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: February 18, 2020
    Assignee: GuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Patent number: 10556019
    Abstract: The invention relates to a nucleic acid molecule for use in a method of treatment of cancer. The nucleic acid molecule comprises a sequence selected from SEQ ID NO 001 to SEQ ID NO 038. The nucleic acid molecules provided are not provided for the treatment of laryngeal cancer.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: February 11, 2020
    Assignee: UNIVERSITÄTSKLINIKUM JENA
    Inventors: Ralf Mrowka, Axel Gohring
  • Patent number: 10550394
    Abstract: Provided herein, inter alia, are compounds capable of binding HSP70 (e.g. mHSP70) on a cell and internalizing into said cell. The compositions provided herein may be useful for delivering therapeutic and diagnostic agents to a cell. Further provided are pharmaceutical compositions and methods of treatment using nucleic acid compounds provided herein.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: February 4, 2020
    Assignees: CITY OF HOPE, APTERNA LTD
    Inventors: John J. Rossi, Sorah Yoon, Nagy Habib
  • Patent number: 10538766
    Abstract: This disclosure relates to methods and compositions for managing vascular conditions by targeting microRNA. In certain embodiments, the disclosure relates to antisense, RNA interference, and blocking oligonucleotide therapeutic compositions and uses related thereto.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: January 21, 2020
    Assignees: Emory University, Georgia Tech Research Corporation
    Inventors: Hanjoong Jo, Dongju Son, Wakako Takabe, Sandeep Kumar, Hhaiwei Qiu, Chanwoo Kim
  • Patent number: 10533189
    Abstract: The subject invention pertains to delivering a polynucleotide into a target cell, particularly, into the nucleus of the target cell. The method comprises the steps of contacting the polynucleotide with the cell and applying pressure on the polynucleotide and the cell in a manner that forces the polynucleotide into the cell. The pressure can be between about 0.1 Pa to about 50 Pa; whereas, the polynucleotide is contacted with the cell at a concentration of between about 0.1 ?M and about 100 ?M. The method can be practiced for cells in culture or cells in vivo.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: January 14, 2020
    Assignee: THE CHINESE UNIVERSITY OF HONG KONG
    Inventors: Chung Hang Jonathan Choi, Zhong Chen, Lei Zhang, Huize Li
  • Patent number: 10533177
    Abstract: Long noncoding RNAs (lncRNAs) are identified that enhance pluripotency reprogramming of somatic cells as well as differentiation of pluripotent cells. Induced pluripotent stem (iPS) cell generation from somatic cells leads to the upregulation and downregulation of identified lncRNAs. The modulation of these lncRNAs are capable of enhancing pluripotency of somatic cells as well as enhancing differentiation of a pluripotent cell.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: January 14, 2020
    Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Daniel H. Kim, Barbara J. Wold
  • Patent number: 10526606
    Abstract: Materials and methods for treating cancer (e.g., by reducing metastasis) are provided herein. For example, materials and methods for treating cancer by targeting WSB1 and/or pVHL are provided.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: January 7, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Zhenkun Lou, JungJin Kim, SeungBaek Lee
  • Patent number: 10526602
    Abstract: This invention relates generally to segmented oligonucleotides capable of modulating gene expression. Specifically, the instant invention relates to segmented microRNA (miRNA) oligonucleotides, including segmented miRNA precursors and segmented pre-microRNAs. The invention also relates to compositions comprising such segmented oligonucleotides, as well as to methods of making and using such oligonucleotides for diagnosis and treatment of diseases associated or causally linked to aberrant levels or activities of gene expression, including aberrant levels of coding and/or non-coding RNA.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: January 7, 2020
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Guillaume Chorn, Lee Lim, Lihong Zhao
  • Patent number: 10526605
    Abstract: The invention provides siRNA compositions that specifically downregulates expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD).
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: January 7, 2020
    Assignee: Purdue Research Foundation
    Inventors: Wanqing Liu, Yoon Yeo
  • Patent number: 10526604
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a nrRNA in an animal. Also provided herein are methods, compounds, and compositions for treating, ameliorating, delaying or reducing a symptom of a disease or disorder associated with a nuclear-retained RNA in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a disease or condition associated with a nuclear-retained RNA, or a symptom thereof.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: January 7, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Huynh-Hoa Bui, Kenneth W. Dobie
  • Patent number: 10519448
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Brain derived neurotrophic factor (BDNF), in particular, by targeting natural antisense polynucleotides of Brain derived neurotrophic factor (BDNF). The invention also relates to the identification of these antisense oligonecleotides and their use in treating diseases and disorders associated with the expression of BDNF.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: December 31, 2019
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito
  • Patent number: 10494631
    Abstract: The invention relates to modified siRNA compounds which down-regulate target gene expression, to pharmaceutical compositions comprising such compounds and to methods of treating and/or preventing the incidence or severity of various diseases or conditions associated with the genes and/or symptoms associated with such diseases or conditions.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: December 3, 2019
    Assignee: Quark Pharmaceuticals, Inc.
    Inventor: Sharon Avkin-Nachum
  • Patent number: 10487359
    Abstract: Method of diagnosing fibromyalgia based on microRNAs. The invention provides a method for the molecular diagnosis of fibromyalgia patients, based on the analysis of the possible alteration of the levels of specific microRNAs in peripheral blood mononuclear cells. The method comprises the analysis of the levels of the microRNAs miR-223, miR-451, miR-338, miR-143 and miR-145 and the diagnosis of fibromyalgia when at least one, or preferably several thereof have decreased levels with respect to a reference value, which preferably is the level of each microRNA in healthy individuals. Three additional microRNAs are also provided, miR-21, miR-1260b and miR-1908, which can be used as negative controls to confirm the diagnosis. The method facilitates an objective diagnosis of fibromyalgia based on molecular markers that are determined from a sample such as blood, which is easy to obtain and process.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: November 26, 2019
    Assignee: UNIVERSIDAD CATÓLICA DE VALENCIA “SAN VICENTE MÁRTIR”
    Inventors: Elisa Oltra García, Germán Cerdá Olmedo, Armando Vicente Mená Durán, María García Escudero, Vicente Juan Monsalve Dolz